How to diagnose a sales cycle that suddenly doubled
When pipeline volume and close rates hold steady but deals take twice as long, the diagnostic lives upstream of sales. Three structural causes look identical from your dashboard and require completely different responses.
By Stacey Tallitsch | May 20, 2026
You pulled the last quarter of pipeline data on Monday morning. Volume looks fine. Close rate looks fine. The average days-to-close column doubled. Deals that used to close in 28 days are sitting at 55. Some are at 90. Your sales lead says push harder. Your marketing lead says do more nurture. Your board says wait it out, the market is soft. Three different prescriptions and not one of them tells you what is actually broken.
Here is what nobody on that list will say out loud. A doubled sales cycle is almost never a sales execution problem. The team did not get worse at their jobs in 60 days. The diagnostic lives upstream of sales, and there are three distinct structural causes that look identical from a pipeline report and require completely different responses. Pick the wrong one and you spend a quarter optimizing the layer that was never the problem.
The first cause: the buying committee on the other side just grew
The macro picture is documented and not in dispute. Harvard Business Review's foundational research on the new B2B sales imperative put the average B2B buying group at 6.8 stakeholders. More recent Gartner work tracks the same number between 6 and 10 today, and into the 8 to 13 range for larger enterprise deals. The trajectory has only gone one direction for a decade.
The operational consequence is the part that does not get explained inside founder communities. Every additional stakeholder is not a 10% longer cycle. It is multiplicative friction. The buyer adds a security reviewer, an IT compliance check, a procurement gate, a department head sign-off. Each one demands a meeting, a document, and a calendar coordination loop. Three weeks evaporate while your pipeline reports stay green and your sales team gets blamed for stalling deals.
The diagnostic is simple and you can do it before lunch. Pick five deals that closed last quarter and five that closed twelve months ago. Count the named human beings involved in each close. Not titles. Not departments. Named humans who touched the deal. If the recent five involve more people, your sales cycle did not lengthen because of execution. Your buyer's organization changed shape.
The right response is not pushing harder. It is buyer enablement built for the new committee. Documents your champion can forward without explaining. Reference architectures that satisfy a CISO who never spoke to you. Pricing logic that procurement can model independently. Most founder-led businesses under $10M are still running a single-stakeholder sales motion, and it will continue to underperform until the materials match the room.
The second cause: your ICP drifted and your sales process did not catch up
This one is invisible from the metrics founders watch.
Marketing was working. Brand awareness climbed. The content engine produced. Six months later your average deal size is 30% larger, which looks like good news on the P&L. Your close rate held. Your win rate held. But the average days-to-close doubled.
Here is the structural truth. Companies cross a size threshold and the way they buy fundamentally changes. Below 50 employees, a CEO can sign a purchase order on a Tuesday afternoon. Above 200 employees, the same purchase needs legal review, finance approval, and a quarterly budget cycle. The buyer's calendar is no longer your calendar. The deal is still real. The rep is not failing. The rep is running a 30-day play into a 90-day buyer.
What happened: your marketing got better at attracting larger orgs while your sales process stayed built for SMB speed. Your reps are operating at the wrong cadence for the company on the other side. They are not stuck because they lost their edge. They are stuck because the rhythm of the room changed and nobody told them.
The diagnostic question is one number. In the last 90 days, what is the median employee count of the companies in your active pipeline compared to your closed-won deals from twelve months ago? If you cannot pull that number from your customer database, pull it before you do anything else. It will take an analyst two hours and it will tell you more than your dashboard has told you all quarter.
If the answer is that you drifted upmarket without noticing, you have two real choices. Rebuild the sales process for the buyer you are now attracting, which means longer cadences, multi-threading from the first call, and proposal logic that survives procurement. Or rebuild your marketing to re-anchor your inbound to the original customer profile you actually know how to close. Both work. The wrong answer is to leave the marketing pulling in 200-person buyers while the sales team keeps trying to close them like 20-person buyers.
The third cause: your pricing anchor broke
A category competitor changed their pricing. Or a category-adjacent platform changed theirs. Or AI tooling collapsed the perceived value of what you charge for. Your buyer is no longer evaluating you against last year's anchor. They are spending three extra weeks comparison-shopping a price they assumed they understood twelve months ago.
You did not change your pricing. The reference frame around your pricing changed. The result looks identical to a buying committee expansion from your pipeline reports, but it is not the same problem and the fix is not the same.
The diagnostic for this one is not in your metrics dashboard. It is in your lost-deal notes and your sales call recordings. Listen for buyers asking why your offer is priced this way, how it compares to an adjacent category they did not used to compare you against, or whether you can match a price point they did not used to surface. Those are anchor-breakage signals. They were not there 90 days ago. They are there now.
This connects directly to the argument in our earlier piece on why your marketing problem is probably a pricing problem. The fix is not faster sales execution. The fix is either repositioning the offer so the comparison is against a different category, restructuring pricing so the buyer cannot directly compare, or accepting that your price point has to move. Pushing harder against a broken anchor is how you turn slow deals into lost deals.
The turn
The reason founders default to "the team needs to push harder" is that it is the only response that does not require changing anything. You do not have to rebuild materials. You do not have to rebuild the sales process. You do not have to confront a pricing problem. You just have to demand more activity from the team you already have.
It feels like leadership. It is actually avoidance.
Every structural cause above looks identical from a top-line pipeline report. The diagnostic work is not the metrics dashboard. It is sitting with five recent deals and five deals from a year ago and asking three questions: how many people were involved, how big were the buyer's organizations, and what did the lost-deal reasons sound like. Twenty minutes of comparison work will tell you which of the three you are facing. Sometimes two of them at once.
This is also where the most common mismatched prescription gets handed out. Marketing leaders prescribe more nurture. Sales leaders prescribe more activity. Pricing consultants prescribe a pricing audit. None of them prescribe a diagnostic first. We covered the same pattern in our earlier piece on reading a marketing dashboard when revenue is flat — the prescription almost always arrives before the diagnostic, and the wrong prescription is worse than no prescription at all.
What to do this week
Before your next pipeline review, pull two cohorts. Five deals closed in the last 90 days. Five deals closed in the same quarter twelve months ago. For each deal, write down three data points. The number of named human beings on the buyer side who touched the deal. The employee count of the buyer's company. A two-sentence summary of the deal's primary internal objection.
Lay the two cohorts next to each other. The differences are not subtle. One of the three patterns will jump out, sometimes two at once. That is your structural cause. The prescription comes from naming the cause correctly, not from prescribing harder execution against an unnamed one.
If the cohorts look identical — same stakeholders, same buyer size, same objection pattern — then the cycle did not actually double for structural reasons and you have a different problem to diagnose. We covered the related question of whether your next executive hire should be marketing or sales for founders facing the same diagnostic confusion at the leadership layer. The principle transfers. Constraint analysis runs before prescription. Always.
A doubled sales cycle is information, not a verdict. It is your buyer telling you something about how they buy now. Read it.
— Stacey Tallitsch, Stronghold CMO
About the Author
Stacey Tallitsch is the President of Stronghold CMO, a Fractional AI CMO service operating under Talisman Capital, Inc. He is a 30-year tech veteran and the author of 21 books on systems thinking, operator-grade decision-making, and personal sovereignty, with more than 30,000 students across his Udemy course catalog.